Clinical Trial Update: Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma [Phase 1]

View source ↗

Summary

A Phase 1, single-arm trial evaluating tumor-treating fields in combination with nivolumab and ipilimumab for metastatic uveal melanoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: HonorHealth Research Institute | Conditions: Uveal Melanoma | Phase 1 | Status: COMPLETED